Risk of Bias Evaluation of Cross-Sectional Studies: Adaptation of the Newcastle-Ottawa Scale
Abstract
ABSTRACT Cross‐sectional studies are widely utilized in medical research to estimate prevalence and examine associations. As such, they can serve as a significant source of data for systematic reviews. However, specific considerations are necessary when evaluating the risk of bias (RoB) of cross‐sectional studies, as several potential biases can undermine the validity, reliability, and robustness of their findings. This article introduces a novel, context‐specific tool designed to assess the RoB of cross‐sectional studies for use in systematic reviews. The proposed tool represents an adaptation of the Newcastle‐Ottawa Scale (NOS), originally developed for cohort and case–control studies. Similar to the original NOS, the new tool (named “NOS‐xs”) features a nine‐star rating system to assess six specific items across three main domains: (i) study sample selection, (ii) assessment of exposure(s) and outcome(s), and (iii) confounding factors. Based on the number of awarded stars, studies are categorized as having high (0–3 stars), moderate (4–6 stars), or low (7–9 stars) RoB. The NOS‐xs tool maintains consistency with the original NOS tool, facilitating its integration into systematic reviews that also include cohort and/or case–control studies. While the NOS‐xs is suited to analytical cross‐sectional studies (i.e., association studies), a simplified version (“NOS‐xs2”) is also introduced for descriptive cross‐sectional studies (i.e., prevalence studies). The NOS‐xs2 features a…
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.